企業概要
Alpha Cognition Inc. is a biopharmaceutical enterprise focused on the development of therapeutic interventions for patients afflicted by neurodegenerative conditions within the United States and Canadian markets. The company operates within the healthcare sector and specifically functions in the biotechnology industry, a domain characterized by high research intensity and long development cycles for novel drug candidates. Its current market capitalization stands at $138.92M, while annual revenue over the trailing twelve months (TTM) amounts to $10.22M. The company's employee count is not publicly disclosed in available data, indicating a focus on capital-intensive R&D rather than large-scale workforce expansion at this stage. These valuation and revenue metrics suggest the firm is in a growth-oriented phase where market value is driven primarily by potential future asset approval and commercialization rather than current profitability, positioning it as a mid-cap entity with significant upside potential contingent on clinical trial success.
財務健全性
The company reported total revenue of $10.22M for the trailing twelve months, yet recorded a net loss of $20,669,876, resulting in a net income of -$20.67M. The substantial gap between revenue and net income reveals a cost structure dominated by significant research and development expenditures and operational expenses typical of early-stage biotechnology firms. EBITDA further reflects this operational intensity, standing at -$22,602,116, which indicates that core business operations are currently generating negative cash earnings before interest, taxes, depreciation, and amortization. Free cash flow is reported at -$14,043,052, meaning the company is burning cash to fund its scientific pipeline rather than generating surplus liquidity from operations. Despite the negative operating performance, the firm maintains a robust cash reserve of $66.05M, providing a substantial buffer to sustain operations and fund ongoing clinical trials without immediate external financing. In terms of profitability metrics, the gross margin is healthy at 81.3%, suggesting efficient production costs relative to revenue, whereas the operating margin of -283.7% and profit margin of -202.2% highlight the heavy overhead and investment costs inherent to the biotech sector. The balance sheet shows zero debt and a current ratio of 8.65, indicating a highly conservative liquidity position with ample short-term assets to cover liabilities. Return on Equity (ROE) is -40.7% and Return on Assets (ROA) is -21.7%, metrics that reflect the company's current inability to generate returns on capital but are consistent with the reinvestment strategy required for drug development.
バリュエーション評価
Valuation multiples for Alpha Cognition Inc. reflect its status as a pre-profitability biotechnology asset. The trailing twelve-month P/E ratio is not available (N/A) due to negative earnings, while the forward P/E is listed at -33.58, a figure that underscores the expectation of future earnings normalization or sustained losses in the near term. The price-to-book ratio stands at 2.22, indicating that the market values the company at more than double its net asset value, which suggests a premium assigned to the company's intellectual property and potential pipeline assets. Additionally, the price-to-sales ratio is 13.59 and the EV/EBITDA is -3.22, providing alternative perspectives that value the firm on its revenue generation capabilities rather than current earnings power. Regarding price action, the stock has traded between a 52-week low of $3.75 and a 52-week high of $11.54, with the current market capitalization of $138.92M implying a valuation that sits significantly below the recent 52-week highs but above the lows. The beta coefficient is 2.52, which signifies that the stock price exhibits high volatility and is expected to fluctuate with much greater magnitude than the broader market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both not available (N/A) in the current dataset, likely due to the immaturity of the company's commercialization efforts or recent restructuring. Consequently, it is impossible to determine if earnings are growing faster or slower than revenue based on historical growth rates provided in the facts. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that all generated cash is retained to fund research operations rather than distributed to shareholders. This reinvestment strategy is standard for biotechnology firms in the development phase, where capital is prioritized for advancing clinical trials and regulatory submissions over shareholder distributions. The overall growth and income profile is characterized by zero current income distribution and a reliance on external capital markets or internal cash reserves to sustain operations while pursuing long-term commercialization milestones for products like ZUNVEYL.